Expression pattern of genes associated with tumor microenvironment in prostate cancer
Keywords:
CAF, cancer-host interaction, clinically significant expression patterns, immune-related alterations, prostate tumors, relative gene expression, TAM, tumor microenvironmentAbstract
Summary. Aim: To assess relative expression (RE) levels of CAF-, TAM-specific, immune defense-associated genes in prostate tumors and to show correlation of RE with clinical, pathological and molecular characteristics, with the aim to define clinically significant specific alterations in a gene expression pattern. Methods: RE of 23 genes was analyzed by a quantitative polymerase chain reaction in 37 freshly frozen samples of prostate cancer tissues of a different Gleason score (GS) and at various tumor stages, compared with RE in 37 paired conventionally normal prostate tissue (CNT) samples and 20 samples of prostate adenomas. Results: Differences in RE were shown for 11 genes out of 23 studied, when tumor samples were compared with corresponding CNTs. 7 genes, namely ACTA2, CXCL14, CTGF, THY1, FAP, CD163, CCL17 were upregulated in tumors. 4 genes, namely CCR4, NOS2A, MSMB, IL1R1 were downregulated in tumors. 14 genes demonstrated different RE in TNA at different stages: CXCL12, CXCL14, CTGF, FAP, HIF1A, THY1, CCL17, CCL22, CCR4, CD68, CD163, NOS2A, CTLA4, IL1R1. RE changes of 9 genes — CXCL12, CXCL14, HIF1A, CCR4, CCL17, NOS2A, CTLA4, IL1R1, IL2RA — were found in tumors with different GS. Moreover, 9 genes showed differences in RE in TNA, dependently on the presence or absence of the TMPRSS2/ERG fusion and 7 genes showed differences in RE of groups with differential PTEN expression. Significant correlations were calculated between RE of 9 genes in adenocarcinomas and the stage, and GS; also, between RE of 2 genes and the fusion presence; and between RE of 4 genes and PTEN expression. Conclusions: Several gene expression patterns were identified that correlated with the GS, stage and molecular characteristics of tumors, i.e. presence of the TMPRSS2/ERG fusion and alterations in PTEN expression. These expression patterns can be used for molecular profiling of prostate tumors, with the aim to develop personalized medicine approaches. However, the proposed profiling requires a more detailed analysis and a larger cohort of patients with prostate tumor.
References
Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 2011; 57: 1366–75.
Khemlina G, Ikeda S, Kurzrock R. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat Rev 2015; 41: 761–6.
Ruggero K, Farran-Matas S, Martinez-Tebar A, et al. Epigenetic regulation in prostate cancer progression. Curr Mol Biol Rep 2018; 4: 101–15.
Zahalka AH, Arnal-Estapé A, Maryanovich M, et al. Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science 2017; 358: 321–6.
Kluth LA, Shariat SF, Kratzik C, et al. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol 2014; 32: 669–76.
Solomon I, Voiculescu VM, Caruntu C, et al. Neuroendocrine factors and head and neck squamous cell carcinoma: an affair to remember. Dis Markers 2018; 2018: 9787–831.
Bryant G, Wang L, Mulholland DJ. Overcoming oncogenic mediated tumor immunity in prostate cancer. Int J Mol Sci 2017; 18: pii: E1542.
Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila) 2016; 9: 895–905.
Kwon OJ, Zhang L, Ittmann MM, et al. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A 2014; 111: E592–600.
Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol 2015; 5: 128.
Puhr M, De Marzo A, Isaacs W, et al. Inflammation, microbiota, and prostate cancer. Eur Urol Focu 2016; 2: 374–82.
Sfanos KS, Yegnasubramanian S, Nelson WG, et al. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol 2018; 15: 11–24.
Lorion R, Bladou F, Spatz A, et al. Prostate cancer microenvironment: Its structure, functions and therapeutic applications. Prog Urol 2016; 26: 464–76.
Eder T, Weber A, Neuwirt H, et al. Cancer-associated fibroblasts modify the response of prostate cancer cells to androgen and anti-androgens in three-dimensional spheroid culture. Int J Mol Sci 2016; 17. pii: E1458.
Attieh Y, Vignjevic DM. The hallmarks of CAFs in cancer invasion. Eur J Cell Biol 2016; 95: 493–502.
Hu W, Qian Y, Yu F, et al. Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma. Oncol Lett 2015; 10: 1390–6.
Maolake A, Izumi K, Shigehara K, et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. Oncotarget 2017; 8: 9739–51.
Parisi L, Gini E, Baci D, et al. Macrophage polarization in chronic inflammatory diseases: killers or builders? J Immunol Res 2018; 2018: 8917804.
Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 2013; 33: 1478–83.
Danaher P, Warren S, Dennis L, et al. Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer 2017; 5: 18. DOI 10.1186/s40425-017-0215-8.
Rådestad E, Egevad L, Jorns C, et al. Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue. Oncotarget 2017; 8: 60257–69.
Sutcliffe S, De Marzo AM, Sfanos KS, et al. MSMB variation and prostate cancer risk: clues towards a possible fungal etiology. Prostate 2014; 74: 569–78.
Langat DK, Sue Platt J, Tawfik O, et al. Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma. J Reprod Immunol 2006; 71: 75–86.
Gerashchenko GV, Mevs LV, Chashchina LI, et al. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion. Exp Oncol 2018; 40: 1–8.
Gerashchenko G, Mankovska O, Dmitriev A, et al. Epithelial-mesenchymal transition related gene expression in prostate tumours. Biopolym Cell 2017; 33: 335–55.
Rosenberg E, Gerashchenko G, Hryshchenko N, et al. Expression of cancer-associated genes in prostate tumors. Exp Oncol 2017; 39: 131–7.
Mevs L, Gerashchenko G, Rosenberg E, et al. Detection of prostate specific ETS fusion transcripts in cancer samples. Biopolym Cell 2017; 33: 256–67.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statist Society 1995; 57: 289–300.
Gerashchenko GV, Grygoruk OV, Mevs LV, et al. PTEN-dependent changes of gene expressions in human prostate tumors. Factors Experim Evol Organisms 2018; 22: in press.
Tolkach Y, Kristiansen G. The heterogeneity of prostate cancer: a practical approach. Pathobiology 2018; 85: 108–16.
Cheng L, MacLennan GT, Lopez-Beltran A, et al. Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice. Expert Rev Anticancer Ther 2012; 12: 1371–4.
Runa F, Hamalian S, Meade K, et al. Tumor microenvironment heterogeneity: challenges and opportunities. Curr Mol Biol Rep 2017; 3: 218–29.
Yang Z, Peng YC, Gopalan A, et al. Stromal hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer. Dis Model Mech 2017; 10: 39–52.
Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med 2014; 211: 1503–23.
Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res 2016; 76: 4124–35.
Graff JN, Puri S, Bifulco CB, et al. Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res 2014; 2: 399–403.
Dagenais M, Dupaul-Chicoine J, Douglas T, et al. The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. Oncoimmunology 2017; 6: e1287247.
Galon J, Pagès F, Marincola FM, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012; 10: 1–20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
